Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

ent of elderly patients with high risk diffuse large B-cell lymphoma (DLBCL) relapse after treatment with R-CHOP. Treatment options for patients who are ineligible for autologous stem cell transplant are limited. In this analysis, of the 63 patients enrolled on the study, 39 patients had been treated with Zevalin. The median age is 75 years (range 62-86); Karnofsky performance status was <80 percent in 59 percent of patients with a median performance status of 70 percent; prognostic score was high-intermediate/high in 53 percent and 47 percent of patients, respectively. Moderate or high impact comorbidity is present in 86 percent. In the intent-to-treat population, progression-free (PFS) and overall survival (OS) were 59 percent and 65 percent, respectively, at 22 months. In the 39 patients who received Zevalin, PFS and OS were 78 percent and 82 percent, respectively, at 26 months. Responses improved in 11 patients who received Zevalin, with eight patients improving from an unconfirmed (CRu) to a confirmed complete response (CR) and three patients improving from a partial response (PR) to a CR/CRu. The side effects reported included blood count suppression: 26 percent and 36 percent grade 3/4 neutropenia, 15 percent grade 3 anemia, and 36 percent and 31 percent grade 3/4 thrombocytopenia. Six patients had delayed blood count recovery for more than 12 weeks. One patient developed myelodysplasia and two patients died after Zevalin was given, one from a suspected brain hemorrhage and one from congestive heart failure.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

R
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CITY, Calif., Aug. 3, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... business update and reported financial results for the three ... Business highlights include: , On July 23, 2015, ... adopted a positive opinion for Zalviso™ for the management ...
(Date:8/3/2015)... August 3, 2015 ReportsnReports.com ... research with 2020 forecasts as well as Global ... medical devices intelligence collection of its library. ... with 2020 forecasts spread across 164 pages, talking ... tables and figures is now available at ...
(Date:8/3/2015)... 3, 2015  Depomed, Inc. (NASDAQ: DEPO ) ... plc,s (NASDAQ: HZNP ) ("Horizon") announcement that it ... Board") set a record date to determine the shareholders ... The Depomed Board will review the request when it ... and contains the information required under Depomed,s bylaws, the ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6
... Sigma-Aldrich Corporation (Nasdaq: SIAL ) will be presenting ... 31st Annual Cowen and Company Healthcare Conference on Tuesday, March ... presenting at 10:15 AM (EST). Barclays Capital 2011 Global ... Hotel, Miami, FL, presenting at 10:15 AM (EDT). ...
... SPRING, Md., March 4, 2011 New data suggest ... increase the risk for the birth defects cleft lip ... use the medication during pregnancy, the U.S. Food and ... ) Before prescribing topiramate, approved to treat ...
Cached Medicine Technology:FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate 2FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate 3
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Nathan’s Famous was recently ... small, medium, and large businesses making an impact in their industry. Andrew Tropeano, the ... how the famous hot dog maker now offers a 50% Reduced Fat All-Beef ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA and the program's ... depression. Depression affects millions of Americans every single year. To help people obtain ... viewers with the latest segment produced with the assistance of several top medical ...
(Date:8/4/2015)... KS (PRWEB) , ... August 04, 2015 , ... ... today their partnership to make the Isabel Symptom Checker available to all users ... consumers a mechanism to check their symptoms in an easy, intuitive method, provides ...
(Date:8/3/2015)... ... 04, 2015 , ... Keeping strong to their ongoing commitment ... today announced extra savings on Florida Physical Therapy continuing education packages. ... on Physical Therapy Flex packages by entering the promo code "FL229" ...
Breaking Medicine News(10 mins):Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:Elite Online CE Provider Offers Discounted Flexible Packages to Meet Florida Physical Therapy Continuing Education Requirements 2
... , , ... ViroPharma Incorporated (Nasdaq: VPHM ... Committee supports the FDA,s Office of Generic Drugs (OGD) draft guidelines ... used to treat severe, often life-threatening bacterial infections of the gastrointestinal ...
... , , ALISO VIEJO, Calif., Aug. ... ), a premier anatomic pathology and molecular testing services resource for pathologists, ... quarter and six months ended June 30, 2009. Financial results included ... versus the second quarter of 2008, and a 43 percent increase in ...
... 4 /PRNewswire-FirstCall/ - Covidien (NYSE: COV ), a ... Inc. (TSX:NRI), a Canadian drug development company, today announced ... set a new action date under the Prescription Drug ... solution 1.5% w/w of November 4, 2009. , During ...
... delivery was vaginal or C-section doesn,t matter, study finds ... anesthesia during a Cesarean delivery doesn,t increase the risk ... , "We found that the incidence of learning disabilities ... those who were delivered via C-section but with general ...
... 5 years after the attacks, but asthma rates have steadily ... People directly exposed to the horrors of the Sept. 11, ... City were reporting new symptoms of post-traumatic stress as long ... study has found. , In fact, by 2006-2007, more people ...
... Petition drive by National Center ... captures 1 million signatures , , WASHINGTON, Aug. 4 ... today the 1 millionth signature on their joint "Free Our Health Care ... health care system. , , The millionth signature milestone comes ...
Cached Medicine News:Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 2Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 3Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 2Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 5Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 6Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 7Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 8Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 9Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 10Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 2Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 3Health News:No Link Found Between Birth Anesthesia and Learning Issues 2Health News:For Many, 9/11-Linked Trauma Emerged Years Later 2Health News:For Many, 9/11-Linked Trauma Emerged Years Later 3Health News:One Million Americans - and Counting - Come Out Against President Obama's Health Care Plan 2Health News:One Million Americans - and Counting - Come Out Against President Obama's Health Care Plan 3
... OraQuick is an FDA ... venipuncture whole blood test used ... of HIV-1 infection. This CLIA ... presence of antibodies to HIV-1, ...
... Mononucleosis test is designed to detect ... plasma or whole blood. The QuickVue+ ... of bovine erythrocytes which give a ... extracts prepared from sheep and horse ...
... available point-of-care diagnostic test that can reliably ... A and B. The test uses a ... that assists viral replication by promoting the ... The ZstatFlu substrate is labeled with a ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
Medicine Products: